Oncology

HR-positive/HER2-negative breast cancer treatment landscape focuses on the complexity of the specific cancer type and the treatment differ according to the biomarker status. The trend suggests a greater bend towards personalized medicine based upon patient biomarkers and physiologic characteristics In our last article, we discussed the HR-positive/HER2-negative breast cancer market landscape. Let us focus more on emerging therapies for HR-positive/HER2-negative breast cancer. Current treatment guidelines run along the lines of endocrine therapy as the preferred option for hormone-receptor-positive breast cancer. However, the therapy is not administered in case ...